Lineage Cell Therapeutics EPS LCTX

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Lineage Cell Therapeutics' earnings per share was −$0.19 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.03.

Earnings per share over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	EPS	On a year earlier	Last 12 months
Q2 FY26	Jun 30, 2026	−$0.03	n/a	−$0.19
Q1 FY26	Mar 31, 2026	−$0.03	n/a	−$0.29
Q4 FY25	Dec 31, 2025	$0.00	n/a	−$0.28
Q3 FY25	Sep 30, 2025	−$0.13	n/a	−$0.29
Q2 FY25	Jun 30, 2025	−$0.13	n/a	−$0.18
Q1 FY25	Mar 31, 2025	−$0.02	n/a	−$0.08
Q4 FY24	Dec 31, 2024	−$0.01	n/a	−$0.10
Q3 FY24	Sep 30, 2024	−$0.02	n/a	−$0.12
Q2 FY24	Jun 30, 2024	−$0.03	n/a	−$0.14
Q1 FY24	Mar 31, 2024	−$0.04	n/a	−$0.14
Q4 FY23	Dec 31, 2023	−$0.03	n/a	−$0.13
Q3 FY23	Sep 30, 2023	−$0.04	n/a	−$0.14

Companies in Biotechnology nearest Lineage Cell Therapeutics' size, closest first, today.

Company	EPS, 12 months	Growth
LCTXLineage Cell Therapeutics	−$0.19
PLXProtalix BioTherapeutics	$0.23	+283% a year
MGTXMeiraGTx	$0.71
VCELVericel	$0.46	+283% a year
ADMAAdma Biologics	$0.70	−18% a year
Peer median	$0.58

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.